Dr. Hammers Discusses Combining IDO and PD-1 Inhibitors in RCC

Hans Hammers, MD, PhD
Published: Thursday, Nov 30, 2017



Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the potential combination of IDO inhibitors and PD-1 inhibitors in renal cell carcinoma (RCC).

Interfering in the IDO pathway can result in a tumor microenvironment that allows for a more enhanced immune response, says Hammers.

Early data out of ASCO 2017 showed an improved response rate with the combination of an IDO inhibitor and a PD-1 inhibitor, resulting in a phase III trial comparing that combination to sunitinib (Sutent) in RCC.
 


Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the potential combination of IDO inhibitors and PD-1 inhibitors in renal cell carcinoma (RCC).

Interfering in the IDO pathway can result in a tumor microenvironment that allows for a more enhanced immune response, says Hammers.

Early data out of ASCO 2017 showed an improved response rate with the combination of an IDO inhibitor and a PD-1 inhibitor, resulting in a phase III trial comparing that combination to sunitinib (Sutent) in RCC.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x